CBD has very low affinity for CB receptors. It functions as an antagonist or partial antagonist at endogenous cannabinoid receptors (each CB1 and CB2 receptor sorts in addition to other G-protein-coupled receptors [GPCRs]) by inhibiting total binding of direct ligands, and may act primarily at a